IMA ImageneBio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1835579 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-0.2%
TTM EPS YoY83.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-32.3%
ROA-28.6%
ROIC (approx.)-98.2%
Asset turnover—
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio16.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $800,000 | $3.50M |
| R&D expense | $28.52M | $32.11M |
| SG&A expense | $20.73M | $8.39M |
| Operating income | -$48.45M | -$37.00M |
| Pretax income | -$45.70M | -$36.55M |
| Income tax | -$350,000 | $13,000 |
| Net income | -$45.35M | -$36.57M |
| EBITDA | -$48.05M | -$35.90M |
| EPS (basic) | -9.64 | -22.10 |
| EPS (diluted) | -9.64 | -22.10 |
| Weighted avg. shares (diluted) | — | 48.26M |
| Balance sheet | ||
| Cash & equivalents | $94.53M | $12.12M |
| Short-term investments | $40.82M | $0 |
| Current assets | $140.29M | $12.47M |
| PP&E, net | $0 | $8,000 |
| Total assets | $152.98M | $15.92M |
| Current liabilities | $11.23M | $17.21M |
| Short-term debt | $0 | $7.50M |
| Total liabilities | $19.84M | $17.45M |
| Shareholders' equity | $133.14M | -$160.56M |
| Shares outstanding | — | 48.26M |
| Cash flow statement | ||
| Operating cash flow | -$47.84M | -$21.32M |
| Investing cash flow | -$5.81M | $11.12M |
| Financing cash flow | $135.47M | $6.91M |
| Depreciation & amortization | $400,000 | $1.10M |
| Stock-based compensation | $15.39M | $0 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.